Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lymphedema × pirfenidone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neurofibroma, Plexiform 3 Neurofibromatosis 1 2 Lung Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Radiation Fibrosis Syndrome 1 Precancerous Conditions 1 Pneumonia 1 Neurofibromatoses 1 Nerve Sheath Neoplasms 1 Neoplasms 1 Myofibroma 1 Lymphedema 1 Leiomyoma 1 Colorectal Neoplasms 1 Acute Lung Injury 1

Interventions

Exercise 10 Manual Lymphatic Drainage 9 Low-Level Light Therapy 5 Standard of Care 4 Physical Therapy Modalities 4 Acupuncture Therapy 4 Resistance Training 3 Methods 3 Indocyanine Green 3 Compression Bandages 3 Yoga 2 Technetium Tc 99m Sulfur Colloid 2 Radiotherapy 2 Pentoxifylline 2 Lipectomy 2 High-Energy Shock Waves 2 Exercise Therapy 2 Early Intervention, Educational 2 Control Groups 2 Bevacizumab 2 specific substance maruyama 1 pycnogenols 1 pirfenidone 1 pazopanib 1 carbohydrate-deficient transferrin 1 Wound Closure Techniques 1 Weights and Measures 1 Weight Reduction Programs 1 Vitamin E 1 Transplantation, Autologous 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04243837 2024-04-23

LYT-100 in Patients With BCRL

PureTech

Phase 2 Terminated

50 enrolled 9 charts

Lymphedema

Data powered by HemOnc (CC BY 4.0) Colophon ⚡